These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27278268)

  • 1. Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.
    Sabattini S; Barzon G; Giantin M; Lopparelli RM; Dacasto M; Prata D; Bettini G
    Vet Comp Oncol; 2017 Sep; 15(3):1051-1061. PubMed ID: 27278268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of Kit receptor tyrosine kinase dysregulations in feline cutaneous mast cell tumors.
    Sabattini S; Guadagni Frizzon M; Gentilini F; Turba ME; Capitani O; Bettini G
    Vet Pathol; 2013 Sep; 50(5):797-805. PubMed ID: 23377219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats.
    Dank G; Chien MB; London CA
    Am J Vet Res; 2002 Aug; 63(8):1129-33. PubMed ID: 12171166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive detection of the c-KIT c.1430G>T mutation by mutant-specific polymerase chain reaction in feline mast cell tumours.
    Takanosu M; Sato M; Kagawa Y
    Vet Comp Oncol; 2014 Jun; 12(2):138-42. PubMed ID: 22891713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Stem Cell Factor in Feline Mast Cell Tumour.
    Sakurai M; Iwasa R; Sakai Y; Chambers JK; Uchida K; Morimoto M
    J Comp Pathol; 2018 Aug; 163():6-9. PubMed ID: 30213375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
    Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
    Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of KIT receptor in feline cutaneous mast cell tumors.
    Rodriguez-Cariño C; Fondevila D; Segalés J; Rabanal RM
    Vet Pathol; 2009 Sep; 46(5):878-83. PubMed ID: 19429979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical characterization of feline mast cell tumors.
    Mallett CL; Northrup NC; Saba CF; Rodriguez CO; Rassnick KM; Gieger TL; Childress MO; Howerth EW
    Vet Pathol; 2013 Jan; 50(1):106-9. PubMed ID: 22492208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feline intestinal mast cell tumours: clinicopathological characterisation and KIT mutation analysis.
    Sabattini S; Giantin M; Barbanera A; Zorro Shahidian L; Dacasto M; Zancanella V; Prata D; Trivigno E; Bettini G
    J Feline Med Surg; 2016 Apr; 18(4):280-9. PubMed ID: 25916685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation.
    Hasegawa Y; Shosu K; Tsuji K; Shimoyama Y; Miyama TS; Baba K; Okuda M; Itamoto K; Igase M; Mizuno T
    Sci Rep; 2022 Sep; 12(1):15791. PubMed ID: 36138037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT mutations in mast cell tumours from cheetahs (Acinonyx jubatus) and domestic cats (Felis catus).
    Tamlin VS; Bottema CDK; Campbell-Ward ML; Hanshaw D; Peaston AE
    Vet Comp Oncol; 2021 Jun; 19(2):381-392. PubMed ID: 33506612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors.
    Sabattini S; Bettini G
    Vet Pathol; 2010 Jul; 47(4):643-53. PubMed ID: 20418469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Minichromosome Maintenance Protein 7 and c-KIT as Prognostic Markers in Feline Cutaneous Mast Cell Tumours.
    Dobromylskyj MJ; Rasotto R; Melville K; Smith KC; Berlato D
    J Comp Pathol; 2015 Nov; 153(4):244-50. PubMed ID: 26385324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.
    Letard S; Yang Y; Hanssens K; Palmérini F; Leventhal PS; Guéry S; Moussy A; Kinet JP; Hermine O; Dubreuil P
    Mol Cancer Res; 2008 Jul; 6(7):1137-45. PubMed ID: 18644978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi-institutional retrospective study of 64 cases.
    Evans BJ; O'Brien D; Allstadt SD; Gregor TP; Sorenmo KU
    Vet Comp Oncol; 2018 Mar; 16(1):20-27. PubMed ID: 28168776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
    Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
    Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of c-KIT protein in feline soft tissue fibrosarcomas.
    Smith AJ; Njaa BL; Lamm CG
    Vet Pathol; 2009 Sep; 46(5):934-9. PubMed ID: 19429996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case report of feline mast cell tumour with intertumoral heterogeneity: Identification of secondary mutations c.998G>C and c.2383G>C in KIT after resistance to toceranib.
    Tani H; Hifumi T; Ito K; Kuramoto T; Miyoshi N; Fujiki M; Nakayama T
    Vet Med Sci; 2024 Sep; 10(5):e70003. PubMed ID: 39177283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.